AskGene Pharma, Inc. clinical trials
A subsidiary of Beijing Aosaikang Pharmaceutical Co., Ltd.
The registry lists 5 studies whose lead sponsor is AskGene Pharma, Inc.. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 16, 2026.
- 5studies on the registry
- 1open to participants now
- 1phase 3 study under way
- 2reach primary completion within a year
What it is testing
The drugs AskGene Pharma, Inc.’s studies test, most studies first; none is open now — 3 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
Coming up
2 of AskGene Pharma, Inc.’s studies under way reach primary completion within a year, 1 of them phase 3. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- 2DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- SSep
- OOct
- NNov
All 2
- Dec 2026ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinomaomectatug · Phase 3 · NCT06206733
- Dec 2026A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.NCT05867420
Add all 2 to your calendar (.ics) → With an account.
All 5 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 22
- 323
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- AskGene Pharma, Inc.5 studies
Something wrong with this grouping? Tell us on the Beijing Aosaikang Pharmaceutical Co., Ltd. page.
Studies
Recruiting first, then most recently updated. Showing 5 of 5. All Beijing Aosaikang Pharmaceutical Co., Ltd. studies →
- A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.RecruitingNCT05867420Phase 1/2
Sponsor listed in the registry: AskGene Pharma, Inc.
- ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ AdenocarcinomaActive, not recruitingNCT06206733Phase 3
Sponsor listed in the registry: AskGene Pharma, Inc.
- ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.Active, not recruitingNCT05632939Phase 1/2
Sponsor listed in the registry: AskGene Pharma, Inc.
- A Phase 1 Study of ASKG315 in Patients With Advanced Solid TumorsStatus unknownNCT05509985Phase 1
Sponsor listed in the registry: AskGene Pharma, Inc.
- A Study of ASKG315 in Patients With Advanced Solid Tumors.Status unknownNCT05554666Phase 1
Sponsor listed in the registry: AskGene Pharma, Inc.